Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Recruiting 4Active not recruiting 4Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 49Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 7Skin Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Glioblastoma 4Diabetes Mellitus, Insulin-Dependent, 12 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Advanced Cancer 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Ipilimumab × Clear all
NCT04434560 2022-07-26

Neoadjuvant Immunotherapy in Brain Metastases

Duke University

Phase 2 Terminated
1 enrolled 7 charts
BreastCNSDermatologicGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡